background: Adverse pregnancy outcomes have been associated with maternal celiac disease (CD). In this study, we investigate the effect of treated and untreated maternal CD on infant birthweight and preterm birth.
Introduction
Celiac disease (CD) is a genetically determined, chronic, inflammatory intestinal disease induced by the ingestion of gluten (Green and Jabri, 2003; Green and Cellier, 2007) . CD can be diagnosed at any age, but is most commonly identified in either early childhood or in the third or fourth decades of life (Van Heel and West, 2006) . CD can exist in a very mild form and may go largely undetected as symptoms are often mild and vague such as fatigue often secondary to iron deficiency anemia. The classic signs of CD include diarrhoea with bulky foul smelling, floating stools due to steatorrhoea and flatulence. Malabsorption may occur resulting in weight loss, severe anemia and neurological disorders.
The true prevalence of CD is unknown but is estimated to affect around 1% of the population and is generally under-diagnosed (Rewers, 2005; Van Heel and West, 2006, Green and Cellier, 2007) . Patients who are diagnosed with CD are instructed to follow a gluten-free diet which generally eases symptoms within days or weeks, although histological recovery can take months or even years (Green and Cellier, 2007) .
Low birthweight and preterm birth are strong predictors of newborn mortality and morbidity which reaches far beyond the newborn period (McIntire et al., 1999; Lopez, 2001; Slattery and Morrison, 2002; Thornton et al., 2004; Gardosi et al., 2005) . Adverse pregnancy outcomes such as reduced birthweight, low birthweight, small for gestational age (SGA), miscarriages and preterm birth have been associated with maternal CD (Ciacci et al., 1996; Norgard et al., 1999; Ludvigsson and Ludvigsson, 2001 , Ludvigsson et al., 2005 , Salvatore et al., 2007 . In a population-based Swedish study, Ludvigsson et al. (2005) reported an association between undiagnosed maternal CD and low birthweight, SGA and preterm birth. Women with diagnosed CD, who were presumably treated before giving birth, had no increased risk of poor fetal growth compared with non-celiac women. This is in contrast, however, to an earlier Swedish study that reported both untreated and treated maternal CD increased the risk of low birthweight (Ludvigsson and Ludvigsson, 2001) .
In the present study, we aimed to assess the effect of treated and untreated CD during pregnancy on birthweight, SGA and preterm birth using data from the entire Danish pregnant population over 25 years.
Materials and Methods
Using the Danish Medical Birth Register we identified all singleton live births in Denmark between 1 January1979 and 31 December 2004 and obtained information on their birthweight and gestational age (Knudsen and Olsen, 1998) . By means of the Civil Registration Number, the children were linked to their mothers and legal fathers. The Civil Registration Number is a unique identifier used uniformly across services in Denmark and enables linkage between all the Danish national registers (Pedersen et al., 2006) . This linkage enabled us to obtain information on parity, maternal and paternal age, infant sex and year of birth from the Civil Registration System. Information about CD in the mothers and fathers, and diabetes, hypertension, myocardial infarction and renal disease in the mothers was obtained from the Danish National Hospital Register (Anderson et al., 1999) , which contains information on all inpatient discharges from Danish hospitals since 1977; outpatient attendances have been included in the register since 1995. All treatment is free of charge for Danish residents. Diagnostic information in the Danish National Hospital Register is based on the Danish version of the International Classification of Diseases, 8th revision (ICD-8) from 1977 to 1993, and the International Classification of Diseases, 10th revision (ICD-10) from 1994 to 2007. Mothers were classified as having CD if they had been hospitalized or in outpatient care with a diagnosis of CD (ICD-8: 269.00; ICD-10: K90.0). The time of onset was defined as the first day of the first contact to the hospital with the relevant diagnosis. Children were defined as exposed to a history of maternal diabetes, hypertension, myocardial infarction or renal disease in the mother if the mother was diagnosed with these conditions prior to the birth of the child.
Women were categorized in three groups according to the timing of the diagnosis of CD (women may appear more than once in the cohort if they had more than one pregnancy during . (i) Untreated women included those who were diagnosed after the date of birth of their child; we assume that untreated CD was present during any pregnancy which preceded the diagnosis. (ii) Treated women were those who were diagnosed with CD at least 90 days before the date of the beginning of gestation (date of the beginning of gestation was estimated as date of delivery minus gestational age). (iii) Women without CD included women who were never diagnosed with CD during 1977 -2007; a small percentage of this group may have had undiagnosed disease but they were all assumed not to have CD. We assumed that any person who was diagnosed with CD adopted a gluten free diet and that the treatment took 90 days to take effect. Therefore, we excluded those who were diagnosed during the period from 90 days prior to pregnancy to delivery. We also excluded offspring of celiac fathers because treated paternal CD has been previously linked to lower birthweight and shorter gestational age (Ludvigsson and Ludvigsson, 2001 ). There were no children in the study cohort with two celiac parents.
We considered birthweight records entered in the register as over 5500 g or ,500 g as invalid. Records of birthweight and gestational age were assumed invalid if birthweight was recorded as more than 1500 g and gestational age ,29 weeks. For gestational age 29 -33 weeks records were assumed invalid if birthweight was recorded as over 2800 g. Birthweight had been recorded in 10 g intervals between 1979 and 1990 and in 1 g intervals from 1991 onwards. However, due to a marked digit preference to the nearest 10, 50 and 100 g in the birthweight distribution we assumed that birthweight was recorded in 100 g during the study period.
Gestational age was based on the last menstrual period. This was often corrected by ultrasound measurements particularly in recent years (Pedersen et al., 2007) . Gestational age was considered invalid if it was recorded as less than 23 or more than 44 weeks. Any baby with an invalid or missing birthweight or gestational age was excluded from the analysis.
We defined SGA as birthweight below the 10th percentile of the gestational age and sex-specific distributions. Due to observed increases in mean birthweight over the years, percentiles were also defined separately for four time periods: 1979 -1986, 1987 -1992, 1993 -2000 and 2001 -2004 for SGA determination. Very small for gestational age (VSGA) was defined as birthweight below the fifth percentile of the gestational age, sexspecific and time period distributions. Because birthweight was rounded to the nearest 100 g, cut-offs which included exactly 10 and 5% of weights could not be defined; the nearest lower figures were used instead giving percentages closer to 8 and 4%. Preterm birth was defined as delivery before 37 gestation weeks.
Study cohort
During the study period there were records of 1 563 322 children in the Danish Medical Birth Register. Of these, 29 children were excluded because their mothers were diagnosed during or up to 90 days before pregnancy and 620 because they had celiac fathers. A further 58 331 children were excluded because either their birthweight or gestational age were missing or invalid. The final cohort consisted of 1 504 342 children. We decided to exclude all births between 1 January 1973 and 31 December 1978 from the study cohort because birthweight was recorded in 250 g intervals during that period. Moreover between 1973 and 1977 gestational age of term babies (37 weeks) was recorded in one category.
Statistical analysis
We used linear regression analysis (Montgomery et al., 2001) to examine the association between treated and untreated maternal CD and birthweight. The models were adjusted for parity, infant sex, maternal age, maternal medical history of diabetes, hypertension, myocardial infarction and renal disease, infant year of birth and paternal age, all of which were represented as categorical variables (Table I) . We also adjusted for gestational age, as a continuous variable. Since the relationship between gestational age and birthweight is not linear we used fractional polynomial regression to determine the best functional relationship resulting in a model with four polynomial functions of gestational age. Because birthweight variance was found to vary by gestational age week and the lack of independence in the data we used linear regression analysis with 'robust' variance estimator (White, 1980) .
The associations between maternal CD and SGA, VSGA and preterm birth, were examined using multiple logistic regression. The models for SGA, VSGA and preterm birth were adjusted for parity, maternal age, maternal medical history of diabetes, hypertension, myocardial infarction and renal disease, infant year of birth and paternal age. Because of the lack of independence in the data we used 'robust' variance estimator.
The impact of maternal celiac disease on birthweight and preterm birth
The data analyses estimated the differences in pregnancy outcomes between (i) offspring of mothers with untreated CD and mothers without CD and between (ii) offspring of mothers with treated CD and mothers without CD using a single model with a three category CD variable: no-CD, untreated and treated, with no-CD used as the reference category. Additional analyses on birthweight and SGA were performed by restricting the data to term babies. We also examined whether the effect of CD on birthweight and SGA was the same for nulliparous and multiparous women. This was done by adding a term representing the statistical interaction between CD and parity (nulliparous or multiparous).
To examine the potential confounding effect of maternal smoking on the association between CD and birthweight we restricted the cohort to singleton live births between 1 January 1997 and 31 December 2004 when smoking information was recorded in the Danish National Hospital Register. We estimated the effect of CD on birthweight adjusted for maternal smoking, maternal and paternal age, parity, infant sex, year of birth, gestational age, maternal medical history of diabetes and maternal medical history of hypertension, myocardial infarction and renal disease. We then repeated the same analysis omitting maternal smoking. All statistical analyses were performed using Stata Software 10 (Stata Reference Manual: Release 10. College Station, 2007) .
The study was approved by the Danish Data Protection Agency and the Danish National Board of Health.
Results
The study cohort consisted of 1 504 342 deliveries (836 241 women). During the study period 785 (0.094%) mothers were diagnosed with CD and they had 1451 babies. A total of 346 babies were born following their mothers' diagnosis and were presumed to have been treated for CD while 1105 babies were born before their mothers' diagnosis and treatment of CD. Mean birthweight was 3503 g in the offspring of treated mothers, 3354 g in the offspring of untreated mothers and 3490 g in the offspring of mothers without CD. Women with untreated CD and their partners appeared to be slightly younger than couples in which the woman had treated CD or no history of CD. Women with treated CD were more likely to have diabetes, hypertension, myocardial infarction and renal disease (Table I) .
Birthweight in women with untreated CD versus women without CD
The estimates of the association between untreated CD and birthweight are presented in Table II (Table III) .
Discussion
This study suggests that untreated CD during pregnancy increased the risk of reduced mean birthweight, SGA, VSGA and preterm birth. In contrast, we found no association between treated CD during pregnancy and birthweight or preterm birth. Thus the treatment of women with CD seems to reverse the effects of CD on birthweight The impact of maternal celiac disease on birthweight and preterm birth and preterm birth to a level similar to that in women without CD. The association between untreated CD and birthweight, SGA and VSGA existed even after excluding preterm births. The effect of untreated CD on birthweight appears to be greater in multiparous women compared with first time mothers. The present study is population-based and the second largest to date on this topic. We were able to adjust for several potential confounders and stratify or restrict the data to rule out other potential confounding factors such as co-morbidity and smoking. By using data from the Danish national registers we avoided patient selection and recruitment biases and loss to follow-up. We had almost complete information on gestational age and birthweight. Kristensen et al. (1996) assessed the validity of gestational age data by comparing the information on gestational age in the Medical Birth Register and the medical records using 1982-1987 data. The authors found an 87% agreement between the two sources when gestational age was measured in weeks. However, records of gestational age may suffer from misclassification in part due to different methods of calculation and previous research suggested that preterm births are more likely to have been misclassified (Gjessing et al., 1999) . It could be argued that women with treated CD had better antenatal care and were followed more closely and therefore their gestational age data were less likely to be misclassified compared with untreated celiac women. However, to our knowledge, women with treated CD in pregnancy do not receive different antenatal care compared with pregnant women without CD. Therefore misclassification of gestational age is unlikely to have occurred at a different rate among women with and without CD in our study and should not affect the presented estimates.
Although the present study is population-based and adjusted for several potential confounders there are some limitations. We had information on maternal smoking for those who were born between 1997 and 2004 only. Maternal cigarette smoking is associated with adverse pregnancy outcomes (Delpisheh et al., 2007) and previous research reported an inverse association between smoking and risk of CD (Snook et al., 1996) . Our sensitivity analyses showed that adjustment for maternal smoking had little effect on the reported estimates.
We extracted the information on CD diagnoses from the Danish National Hospital Register. It is likely, given the subclinical nature of CD in many instances, that some women with CD may have been misclassified as non-celiac in the study cohort. The diagnosis of CD is recorded following discharge from, or at the time of outpatient visits at, the hospital and not by screening programs of CD. The Hospital register has been effective from 1977 therefore we will have missed diagnoses of CD before that date. It is widely accepted that clinical CD represents the tip of the iceberg and many patients may have symptoms for a long time and are admitted to hospital several times and undergo surgical procedures before they are diagnosed with CD (Green and Cellier, 2007) . Only 0.09% of the women in the present study were diagnosed with CD (treated or untreated) although the true prevalence in other European populations is estimated to be close to 1% (Rewers, 2005; Green and Cellier, 2007) . On the basis of a 1% true prevalence and 0.09% diagnosed cases of CD (785 women) it is possible that almost 8000 women with CD remain undiagnosed and in our study have been misclassified as nonceliac. However, since this is a tiny proportion of our reference group (women without CD), misclassification of women with CD as nonceliac is unlikely to greatly affect the reported risk estimates: it would tend to lead to underestimation rather than an overestimation of the effect of CD. In contrast, if women who have delivered smaller babies had a better chance of having their CD diagnosed than women who had a baby with an average birthweight, the effect of CD on birthweight could have been overestimated. However, it is not routine clinical practice to test for maternal CD following poor pregnancy outcomes. It is also possible that patients with other diseases may be registered as CD patients more often than patients without any other diseases but this is unlikely to greatly affect the reported risk estimates. Our findings are consistent with the majority of the existing literature (Norgard et al., 1999 , Ludvigsson et al., 2005 , although the magnitude of the effect that we observed is lower than that reported in some of the previous studies (Ciacci et al., 1996; Salvatore et al., 2007) . Our results are similar to those reported by Ludvigsson et al. (2005) , which was based on the Swedish national registers. They reported a 60% increase in risk of SGA (defined as birthweight for gestational age below 22 standard deviations of the mean). Our results are also similar to those reported by Norgard et al. They used the Danish Medical Birth registry data between 1977 and 1992 and found that the mean birthweight of babies born to women with CD prior to their first hospitalization was 238 g [(95% CI) ¼ 150, 325 g) lower than those of the control women. However, the results reported by Norgard et al., were based on data of 211 babies born to 127 celiac mothers although the present study was based on data of 1451 babies born to 785 celiac mothers.
We found that diagnosis of CD before conception and presumed treatment with gluten free diet improves the pregnancy outcome. This finding is consistent with the recent Swedish study (Ludvigsson et al., 2005) and others (Ciacci et al., 1996; Norgard et al., 1999) but contrasts with an earlier Swedish study which reported that even treated maternal CD was associated with lower birthweight (Ludvigsson and Ludvigsson, 2001) . However, the early study (Ludvigsson and Ludvigsson, 2001 ) was based on only 53 live births of mothers with CD, although the later study (Ludvigsson et al., 2005) was based on 2078 offspring of celiac mothers.
The exact mechanisms whereby untreated maternal CD results in preterm delivery or smaller babies are unknown. It has been hypothesized that the adverse effect of untreated CD on birthweight and risk of preterm delivery may be due to nutritional deficiencies as a direct consequence of malabsorption. However, several studies have suggested that malabsorption or malnutrition is not a consistent feature in women with CD and adverse pregnancy outcome, nor does it appear that severity of symptoms is related to the degree of adverse outcome (Ciacci et al., 1996) . Another possible mechanism may be the direct adverse effect of maternal auto antibodies, such as anti-tissue transglutaminase, on placental function (Hager et al., 1999) . The presence of these antibodies at the feto-placental interface may result in compromised nutrient transfer, altered cell dynamics, suppression of growth factors and altered secretory function. We found the association between untreated CD and birthweight measures to be more pronounced in women who had previously given birth. In general, birthweight for gestational age increases from first to second pregnancy (Beaty et al., 1997) . Whether our finding is due to a true interaction between parity and untreated CD needs further studies as this was not part of our prior hypotheses.
Untreated CD in pregnancy is associated with reduced infant birthweight and increased risks of SGA, VSGA and preterm birth. This study also supports the evidence that treatment of CD reduces the risk of reduced birthweight to that of the general population. Whether pre-pregnancy or antenatal screening of all women and the commencement of gluten free diets of those found to have CD would reduce these risks remains to be shown; however, it seems likely considering our results.
